MDD-001
Major Depressive Disorder · HPA-BDNF-Neuroinflammation Engine · VIZASL v1
MEBICAL · EOSE Fleet · TRB-MEBICAL-HEALTH-DOMAIN-001 · Day 90 · Real data · Cited · Sorries marked
MEBICAL · PSYCH ← RESEARCH
HPA axis (hypothalamus→pituitary→adrenal)
BDNF dimer (shrinking)
Hippocampal volume loss
Cortisol cloud particles
γ₁ floor anchor
PHASES
RX
BIOMARKERS
EEG
NPs
Pathophysiology
HPA Axis Hyperactivation
Hypothalamus-pituitary-adrenal axis dysregulation. Cortisol chronically elevated. CRH-ACTH-cortisol cascade stuck in overdrive. Cortisol crosses BBB → glucocorticoid receptor (GR) activation → hippocampal neurotoxicity. Hippocampal volume reduced 5–10% in chronic MDD.
Nestler et al. 2002 Neuron (MDD neurobiology review)
BDNF Hypothesis
Brain-derived neurotrophic factor reduced in depression. BDNF supports hippocampal neurogenesis (dentate gyrus), synaptic plasticity. Antidepressants increase BDNF. The Castrén hypothesis: depression = BDNF deficiency syndrome. The correlation is strong but not established as causal.
Duman & Monteggia 2006 Biol Psychiatry · Castrén 2005 Trends Neurosci
Neuroinflammation Hypothesis
IL-6, TNF-α, CRP elevated in subset (~30%) of MDD. Neuroinflammation drives IDO pathway → tryptophan → kynurenine (not serotonin). Reduces serotonin precursor. Explains inflammatory subtype. Anti-inflammatory augmentation strategies in trials.
Raison et al. 2010 · Dantzer et al. 2008 Nat Rev Neurosci
Serotonin Hypothesis — SORRY: Overclaimed
Serotonin deficiency theory of depression = widely taught, widely overclaimed. Moncrieff et al. 2022: systematic review found NO consistent evidence of low serotonin in MDD. SSRIs work but the mechanism is NOT simply serotonin replenishment. The field got ahead of the evidence.
Moncrieff et al. 2022 Mol Psychiatry (systematic review — "chemical imbalance" myth critique)
Default Mode Network Hyperactivity
DMN (medial PFC, posterior cingulate, angular gyrus) overactive at rest in MDD. Self-referential rumination. DMN should suppress during tasks but fails to deactivate. Ketamine rapidly suppresses DMN overactivity, correlating with immediate antidepressant effect.
Sheline et al. 2009 PNAS · Hamilton et al. 2011
Pharmacological PROVEN
SSRIs — First-Line
Sertraline, escitalopram, fluoxetine. ~60% response rate in first episode. 4–6 weeks for full effect. Well-tolerated. Mechanism: SERT blockade → synaptic serotonin increase. Works, but not via serotonin deficiency reversal (see SORRY-1).
Cipriani et al. 2018 Lancet (large network meta-analysis of 21 antidepressants)
Ketamine / Esketamine FDA 2019
NMDA antagonist. Rapid antidepressant effect (hours, not weeks). FDA-approved esketamine (Spravato) intranasal for TRD. Mechanism: glutamate AMPA potentiation, BDNF release, DMN suppression. SORRY: durability — effect wanes 1–2 weeks, re-dosing required.
Murrough et al. 2013 Am J Psychiatry (ketamine RCT)
ECT — Most Effective for Severe/TRD
Electroconvulsive therapy. 70–90% response in severe/TRD MDD. Most effective treatment in psychiatry. Mechanism: UNKNOWN. Anticonvulsant theory, BDNF surge, HPA normalisation — all proposed, none proven. SORRY: we use the most effective treatment without knowing why it works.
UK ECT Review Group 2003 · Geddes et al. · SORRY: mechanism unknown
Psilocybin Phase 2/3
Carhart-Harris et al. 2021 NEJM: psilocybin non-inferior to escitalopram at 6 weeks. Phase 3 not complete. FDA Breakthrough Therapy designation. Mechanism: 5-HT2A agonism → default mode network disruption → ego dissolution → neuroplasticity.
Carhart-Harris et al. 2021 NEJM (psilocybin vs escitalopram) · Phase 3 ongoing
rTMS — FDA Cleared
Repetitive transcranial magnetic stimulation. Left DLPFC stimulation. FDA cleared for MDD (2008) and TRD. 4–6 week course. ~50% response in TRD. No anaesthesia. Mechanism: cortical excitability modulation. Deep TMS (H-coil) reaches deeper structures.
O'Reardon et al. 2007 Biol Psychiatry (pivotal trial)
V12 · 2025-2026 Updates
Zuranolone (Zurzuvae) FDA APPROVED 2023
Neurosteroid positive allosteric modulator of GABA-A receptors. Oral, 14-day course. Rapid onset (days, not weeks). FDA approved August 2023 for MDD and PPD (postpartum depression). First oral neurosteroid. Mechanism distinct from SSRIs: directly modulates inhibitory tone rather than monoamine reuptake.
Deligiannidis et al. 2023 NEJM (SKYLARK trial, PPD) · FDA approval Aug 2023
Psilocybin COMP360 Phase 3 · 2025
COMPASS Pathways Phase 3 COMP360 trial: 25mg psilocybin vs 10mg vs 1mg (control) in TRD. Largest psilocybin RCT ever. FDA Breakthrough Therapy Designation for TRD. Phase 3 enrollment completed, results expected 2025-2026. If positive, regulatory submission pathway clear.
Goodwin et al. 2022 NEJM (Phase 2) · COMP360 Phase 3 ongoing 2025
MDMA-Assisted Therapy (MAPP2) Phase 3 · PTSD/MDD adjacent
LYKOS (MAPS PBC) Phase 3 MAPP2 replication study ongoing after FDA rejection of initial PTSD submission. MDD application separate. 5-HT + DA release + oxytocin mechanism. Comorbid PTSD-MDD population substantial overlap. Phase 3 data 2025-2026.
Mitchell et al. 2021 Nat Med (Phase 3 PTSD) · MAPP2 replication 2025
▸ V12 Update · Day 91 · 2026-05-05
Treatment panel updated with latest 2025-2026 clinical data. γ₁ = 14.134725141734693
Biomarker Status LARGEST GAP IN MEDICINE
No Validated Diagnostic Biomarker for MDD
SORRY: MDD is diagnosed entirely clinically (DSM-5 criteria). No blood test, no imaging biomarker, no EEG test confirms MDD. The biomarker gap in psychiatry is the largest in medicine. 30% treatment-resistant. No way to predict who will respond to which drug.
SORRY: This is the fundamental challenge of psychiatric drug development
CRP elevationNeuroinflammation subtype marker. High CRP → poor SSRI response, better anti-inflammatory/immune approach. Not diagnostic. Subtype stratifier research only.
Cortisol awak. responseCAR: cortisol spike 30min after waking. Flattened in MDD. HPA dysregulation marker. Research use.
Sleep EEG REM latencyShortened REM latency (REM starts sooner in sleep) = most replicated biological finding in MDD. Research use only. STRONG
EEG in MDD
Alpha asymmetryReduced LEFT frontal alpha relative to right. Alpha inversely related to cortical activation. Less left frontal activation = approach motivation deficit. Approach/withdrawal model of frontal asymmetry. Davidson 1988 — research biomarker
Theta cordancePredicts antidepressant response (PREDICT study). Low prefrontal theta cordance after 1 week → poor response → switch earlier. Research paradigm. Cook et al. 2002
Sleep REM latency STRONGShortened REM latency in MDD EEG sleep study. First REM period earlier, longer, denser. Most replicated biological finding across MDD research.
DMN resting fMRIHyperactive default mode network at rest. Rumination correlate. Not technically EEG but resting-state oscillations overlap. Ketamine immediately suppresses.
Novel Patterns (8)
SORRYNP-MDD-001 · Serotonin deficiency hypothesis: no consistent evidence of low serotonin in MDD (Moncrieff 2022) — SSRIs work but mechanism is NOT serotonin replenishment
PROVENNP-MDD-002 · ECT most effective treatment in psychiatry (~80% response TRD) · mechanism completely unknown · "we don't know why the best treatment works"
PROVENNP-MDD-003 · HPA axis: cortisol → hippocampal GR activation → neurotoxicity → volume loss · first structural biomarker of depression · reversible with treatment
PROVENNP-MDD-004 · Ketamine: hours vs weeks for effect · NMDA antagonism → glutamate → BDNF → DMN suppression · fastest antidepressant mechanism known
EMERGINGNP-MDD-005 · Neuroinflammation subtype (high CRP): SSRIs don't work, anti-inflammatory approaches might · subtype stratification changes treatment algorithm
OPENNP-MDD-006 · Psilocybin: Phase 2 non-inferior to escitalopram · DMN disruption = ego dissolution = neuroplasticity window · Phase 3 results pending
OPENNP-MDD-007 · REM latency shortening: most replicated biological finding in MDD · still not used clinically · gap between research biomarker and clinical tool
SORRYNP-MDD-008 · No diagnostic biomarker · 30% TRD · ECT mechanism unknown · ketamine durability fails 1-2 weeks · serotonin myth still taught · psychiatry biomarker gap = largest in medicine
V12 · RELEARN LINKS
Sovereign Forcing
All Research Bonsai
Periodic Doctrine
⚠ OPEN SORRIES · MDD-001
SORRY-1 · Serotonin hypothesis overclaimed
Moncrieff et al. 2022 Molecular Psychiatry: systematic umbrella review found no consistent evidence that serotonin levels or activity are reduced in people with depression. SSRIs work, but not by correcting a serotonin deficiency. The "chemical imbalance" story was marketing, not mechanism.

SORRY-2 · ECT mechanism unknown
Electroconvulsive therapy has 70–90% response rates in severe/TRD MDD, making it the most effective psychiatric treatment. The mechanism is completely unknown. Proposed theories include anticonvulsant effect, BDNF surge, HPA normalisation — none established.

SORRY-3 · Ketamine durability
Ketamine produces rapid antidepressant effects in hours but effects typically wane within 1–2 weeks without re-dosing. The maintenance protocol (frequency, duration) is not standardised. Dependency risk with chronic use unclear.

SORRY-4 · No diagnostic biomarker
MDD is diagnosed by clinical interview alone. No blood test, imaging finding, or EEG marker is validated for diagnosis. 30% of patients are treatment-resistant. No predictor of which drug will work for which patient exists.

SORRY-5 · Psilocybin Phase 3 incomplete
Phase 2 data is promising. Phase 3 trials are underway but not complete. Regulatory approval pending outcome. Cannot claim PROVEN status until Phase 3 complete.
MDD-001 · HPA-BDNF-NEUROINFLAMMATION · SEROTONIN MYTH · ECT BEST UNKNOWN MECHANISM · KETAMINE HOURS NOT WEEKS
γ₁ = 14.134725141734693
🐾 TARDIGRADE · MDD-001
"Tardigrades don't avoid radiation. They live in it." — The SORRYs here are not embarrassment. They are radiation this engine now wears as armor. Every open sorry = a denser boundary. Every failed trial = encoded protein.
MEEK · PRIDE & HONOUR DOCTRINE ↗
Depression / MDD · MEBICAL · EOSE Labs Inc. · γ₁ = 14.134725141734693 · V12 · Day 91 · MEBICAL ENGINE ↗ · ALL RESEARCH ↗ · SOVEREIGN FORCING ↗